

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: <b>Tadamitsu Kishimoto <i>et al.</i></b>	)	Confirmation No.: <b>1453</b>
	)	
Application No. <b>10/785,230</b>	)	Group Art Unit: <b>1642</b>
	)	
Filed: <b>February 25, 2004</b>	)	Examiner: <b>Laura B. Goddard</b>
	)	
For: <b>Vascularization Inhibitors</b>	)	Date: <b>May 21, 2009</b>

**INFORMATION DISCLOSURE STATEMENT**

**UNDER 37 C.F.R. 1.97(c)**

Pursuant to 37 C.F.R. 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the document listed on the attached PTO-1449. This Information Disclosure Statement is being filed to the best of the undersigned's knowledge before the mailing date of a Notice of Allowance for the above-referenced application. Each reference contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement, accordingly, pursuant to 37 CFR 97(c)(1) and 1.97 (c), Applicants submit that no fee is necessary.

Each reference cited in this information disclosure statement was first cited in an Office Action, dated April 21, 2009, issued in a corresponding Japanese Patent Application No. JP 2000-537575. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

**Except** for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or

credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a  
**Constructive Petition for Extension of Time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **May 21, 2009**  
Morgan, Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Ave., N.W.  
Washington, D.C. 20004  
202-739-3000

Respectfully submitted  
**Morgan, Lewis & Bockius LLP**

/Robert Smyth/  
Robert Smyth  
Registration No. 50,801